New
ScienceMore in Science→
Atypical GPCR Signaling Tapped as a Target for Cardiac Fibrosis Therapy
Key Takeaways
- Science lists a report on targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy in Volume 393, Issue 6818 (September 2026).
- Cardiac fibrosis replaces working muscle with stiff connective tissue, contributing to heart failure and arrhythmia, and current drugs treat upstream causes rather than the scar itself.
- Atypical, non-canonical GPCR signaling branches can be engaged selectively, which could allow fibrosis-linked pathways to be interrupted without shutting down normal cardiac physiology.
- Key hurdles include fibroblast selectivity, timing of intervention, sustained cardiac delivery, and clinical endpoints that measure fibrosis and function.
DE
DT Editorial Team··via science.org
